Dosing patterns and dose effects of sacubitril/valsartan: A claims-based retrospective cohort study

Jillian M Rung, Tyson S Barrett, Keith LeJeune, Shannon B Richards, Amresh Raina and Lawrence Sinoway

PLOS ONE, 2025, vol. 20, issue 3, 1-13

Abstract: Purpose: The goals of this retrospective cohort analysis were to determine real-world dose and titration patterns of sacubitril/valsartan (SAC/VAL), a heart failure medication, and examine whether dose patterns are associated with healthcare utilization and costs. Methods: Adult health plan members (18-100 years old) who initiated SAC/VAL between 2020 and 2022 and had continuous enrollment 6 months prior to, and at least 3 months following SAC/VAL initiation were identified. Members also had to have 3 months of SAC/VAL fills with good adherence (N = 2,977). Claims data were used to characterize dosage patterns and compare total costs of care, as well as all-cause and heart failure- hospital admissions across those with different terminal SAC/VAL doses. Results: Most members initiated SAC/VAL at the lowest dose (76%, n = 2,267), of whom few titrated upward by their final fill (31%, n = 703). Overall, only 19% (n = 563) were at target by their final fill. Those ending on higher doses experienced significantly fewer all-cause admissions (incidence rate ratios of 1.52 [SE = .16] to 2.66 [SE = .37]; ps

Date: 2025
References: Add references at CitEc
Citations:

Downloads: (external link)
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0320216 (text/html)
https://journals.plos.org/plosone/article/file?id= ... 20216&type=printable (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:plo:pone00:0320216

DOI: 10.1371/journal.pone.0320216

Access Statistics for this article

More articles in PLOS ONE from Public Library of Science
Bibliographic data for series maintained by plosone ().